LENZ

+ Watchlist + Portfolio

LENZ Therapeutics, Inc.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.79
52-Week Range: $3.51 – $49.25
Market Cap: $112.48M
P/E (TTM): —
EPS (TTM): -4.13
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.51
PEG Ratio: —
Return on Equity: -59.21%
Return on Assets: -37.36%
Gross Margin: 91.74%
Operating Margin: -622.89%
Profit Margin: 0.00%
Current Ratio: 13.55
Debt/Equity: 0.00
Total Debt: $569.00K
Free Cash Flow: $-71.25M
Revenue Growth: 9.70%
Earnings Growth: —
Enterprise Value: $-106.95M

LENZ Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$15.00M	$0.00	$0.00	$19.09M
Cost of Revenue	—	—	$0.00	$418.00K
Gross Profit	—	—	$0.00	$18.67M
Research & Development	$21.13M	$59.50M	$29.80M	$18.67M
Selling, General & Admin	$4.36M	$12.93M	$28.81M	$91.14M
Operating Expenses	$25.48M	$72.43M	$58.61M	$109.81M
Operating Income	-$10.48M	-$72.43M	-$58.61M	-$91.14M
EBITDA	-$10.47M	-$72.41M	-$58.55M	-$90.85M
Pretax Income	-$10.46M	-$70.15M	-$49.77M	-$81.63M
Income Tax	$347.00K	-$179.00K	$1.00K	$502.00K
Net Income	-$10.81M	-$69.97M	-$49.77M	-$82.13M
Diluted EPS	-0.42	-2.74	-2.34	-2.85
Diluted Shares	25.53M	25.53M	21.28M	28.81M

LENZ Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$44.44M	$35.14M	$20.16M	$25.18M
Receivables	—	—	$0.00	$329.00K
Inventory	—	—	$0.00	$2.94M
Current Assets	$46.64M	$67.24M	$211.92M	$301.41M
Total Assets	$46.95M	$70.38M	$215.30M	$305.88M
Current Liabilities	$9.50M	$18.51M	$10.41M	$21.19M
Total Debt	$250.00K	$329.00K	$1.38M	$815.00K
Total Liabilities	$71.12M	$163.09M	$11.22M	$21.54M
Retained Earnings	-$25.28M	-$95.25M	-$145.01M	-$227.14M
Shareholders' Equity	-$24.17M	-$92.71M	$204.08M	$284.34M
Working Capital	$37.14M	$48.73M	$201.51M	$280.23M

LENZ Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$4.09M	-$60.38M	-$59.39M	-$69.17M
Capital Expenditure	-$37.00K	-$30.00K	-$468.00K	-$827.00K
Free Cash Flow	-$4.13M	-$60.41M	-$59.86M	-$70.00M
Depreciation & Amortisation	$8.00K	$15.00K	$58.00K	$287.00K
Stock-Based Compensation	$721.00K	$1.34M	$6.37M	$12.55M
Investing Cash Flow	-$37.00K	-$29.62M	-$154.48M	-$75.67M
Financing Cash Flow	$30.26M	$80.70M	$199.00M	$149.75M
Net Change in Cash	$26.13M	-$9.30M	-$14.87M	$4.91M

LENZ Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$5.00M	$12.50M	$1.59M	$1.90M	$5.49M
Cost of Revenue	$0.00	$0.00	—	—	$1.08M	$280.00K
Gross Profit	$0.00	$5.00M	—	—	$825.00K	$5.21M
Research & Development	$5.82M	$9.06M	$3.79M	$0.00	$0.00	$0.00
Selling, General & Admin	$11.11M	$12.80M	$27.60M	$39.63M	$44.96M	$39.38M
Operating Expenses	$16.93M	$21.86M	$31.39M	$39.63M	$44.96M	$39.38M
Operating Income	-$16.93M	-$16.86M	-$18.89M	-$38.46M	-$44.13M	-$34.17M
EBITDA	-$16.89M	-$16.84M	-$18.76M	-$38.36M	-$44.02M	-$34.06M
Pretax Income	-$14.62M	-$14.41M	-$16.70M	-$35.89M	-$41.49M	-$31.91M
Income Tax	—	$500.00K	$0.00	$2.00K	—	$3.00K
Net Income	-$14.62M	-$14.91M	-$16.70M	-$35.90M	-$41.49M	-$31.92M
Diluted EPS	-0.53	-0.53	-0.59	-1.16	-1.32	-1.02
Diluted Shares	27.53M	28.08M	28.54M	31.07M	31.35M	31.37M

LENZ Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$23.04M	$37.61M	$25.40M	$25.18M	$24.77M	$24.21M
Receivables	—	—	—	$329.00K	$343.00K	$442.00K
Inventory	—	—	$949.00K	$2.94M	$3.50M	$4.12M
Current Assets	$197.86M	$213.60M	$207.00M	$301.41M	$268.37M	$233.28M
Total Assets	$201.25M	$217.33M	$210.70M	$305.88M	$272.54M	$236.60M
Current Liabilities	$8.57M	$10.40M	$16.32M	$21.19M	$25.81M	$17.21M
Total Debt	$1.18M	$1.05M	$954.00K	$815.00K	$673.00K	$569.00K
Total Liabilities	$9.24M	$10.97M	$16.78M	$21.54M	$26.04M	$17.33M
Retained Earnings	-$159.63M	-$174.54M	-$191.25M	-$227.14M	-$268.63M	-$300.55M
Shareholders' Equity	$192.01M	$206.37M	$193.93M	$284.34M	$246.49M	$219.26M
Working Capital	$189.29M	$203.20M	$190.68M	$280.23M	$242.56M	$216.07M

LENZ Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$16.05M	-$11.51M	-$8.59M	-$33.02M	-$33.58M	-$38.71M
Capital Expenditure	-$110.00K	-$240.00K	-$439.00K	-$38.00K	-$18.00K	-$16.00K
Free Cash Flow	-$16.16M	-$11.75M	-$9.03M	-$33.06M	-$33.60M	-$38.73M
Depreciation & Amortisation	$36.00K	$19.00K	$125.00K	$107.00K	$111.00K	$110.00K
Stock-Based Compensation	$2.56M	$2.85M	$3.47M	$3.68M	$4.32M	$4.47M
Investing Cash Flow	$18.89M	-$414.00K	-$4.33M	-$89.81M	$33.16M	$37.75M
Financing Cash Flow	$44.00K	$26.49M	$598.00K	$122.61M	$14.00K	$395.00K
Net Change in Cash	$2.88M	$14.57M	-$12.32M	-$220.00K	-$407.00K	-$564.00K

Market Snapshot

About

LENZ Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for ophthalmic conditions. The company's lead product candidate is designed to address presbyopia, the age-related loss of near vision affecting millions of people worldwide. LENZ is advancing novel pharmacological approaches to improve visual function and quality of life for patients with unmet eye care needs.